NASDAQ · XTNT
Healthcare · Medical - Devices
$0.33
Up+$0.01 (+2.19%)
Updated Sep 18, 2026, 12:47 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
XTNT closed at $0.33 after 20 trading sessions, down 1.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $0.321 | $0.3294 | $0.32 | $0.327 | 192.75K |
| Sep 16, 2026 | $0.33 | $0.338 | $0.32 | $0.32 | 266.74K |
| Sep 15, 2026 | $0.33 | $0.33 | $0.3197 | $0.32 | 504.93K |
| Sep 14, 2026 | $0.33 | $0.3418 | $0.3212 | $0.328 | 264.09K |
| Sep 11, 2026 | $0.34 | $0.3458 | $0.3211 | $0.3458 | 246.02K |
| Sep 10, 2026 | $0.3352 | $0.3583 | $0.32 | $0.3439 | 376.39K |
| Sep 9, 2026 | $0.3905 | $0.3905 | $0.3369 | $0.338 | 455.6K |
| Sep 8, 2026 | $0.40 | $0.4081 | $0.373 | $0.3801 | 521.23K |
| Sep 4, 2026 | $0.3941 | $0.4035 | $0.3701 | $0.375 | 380.26K |
| Sep 3, 2026 | $0.40 | $0.4199 | $0.38 | $0.3956 | 642.86K |
| Sep 2, 2026 | $0.391 | $0.4364 | $0.3764 | $0.409 | 8.9M |
| Sep 1, 2026 | $0.372 | $0.4098 | $0.3563 | $0.368 | 767.7K |
| Aug 31, 2026 | $0.362 | $0.4199 | $0.346 | $0.392 | 2.69M |
| Aug 28, 2026 | $0.3452 | $0.4861 | $0.3397 | $0.384 | 77.61M |
| Aug 27, 2026 | $0.32 | $0.3441 | $0.32 | $0.33 | 5.13M |
| Aug 26, 2026 | $0.3209 | $0.3297 | $0.312 | $0.321 | 50.27K |
| Aug 25, 2026 | $0.315 | $0.3282 | $0.312 | $0.3199 | 86.88K |
| Aug 24, 2026 | $0.33 | $0.33 | $0.315 | $0.3228 | 62.22K |
| Aug 21, 2026 | $0.34 | $0.34 | $0.32 | $0.3249 | 143.97K |
| Aug 20, 2026 | $0.3398 | $0.3398 | $0.33 | $0.3333 | 48.5K |
The latest Smart Investors Daily articles mentioning XTNT.
XTNT research
Company profile and research snapshot.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| May 13, 2026 | BTIG | Buy | — |
| Mar 31, 2026 | BTIG | Buy | — |
| Nov 11, 2025 | BTIG | Buy | — |
| May 16, 2024 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 2, 2026
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Xtant Medical Holdings (AMEX:XTNT) with a Buy rating and announces Price Target of $1.
ChartMill · Aug 28, 2026
Friday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!
ChartMill · Aug 27, 2026
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Yahoo · Aug 27, 2026
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced an exclusive partnership with BioHorizons (a Henry Schein, Inc. company), whereby BioHorizons will distribute Xtant's allogeneic growth factor technology under the private brand Prolifica™ through its commercial network.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XTNT.
